- All cancer types
- Brain tumor
- Breast cancer
- Cervical cancer
- Childhood cancer
- Colon cancer
- Endometrial cancer
- Kidney cancer
- Lung cancer
- Multiple myeloma
- Ovarian cancer
- Pancreatic cancer
- Prostate cancer
- Skin cancer
- Stomach cancer
- Testicular cancer
We presented the interim analysis of a randomised clinical trial, showcasing improved patient quality of life, and illustrating the patient experience via real world data.
CareAcross at ASCO 23: Using Patient-Reported Outcomes (PROs) to understand Cancer-Related Thrombosis
Explore the power of patient-reported outcomes (PROs) in understanding cancer-related thrombosis. CareAcross abstract from the American Society of Clinical Oncology (ASCO) congress in Chicago.
Two abstracts featuring real world data presented at WCLC 22: Comparing side-effects between past/current smokers and never smokers; and examining differences in toxicity among platinum-based combinations.
Cancer-related fatigue is a common experience of cancer patients. We showcased the effectiveness of our personalised interventions at the American Society of Clinical Oncology (ASCO) congress in Chicago.
The company shared 2 posters based on real world data analysis from thousands of breast cancer patients. The findings focused on Aromatase Inhibitors and their side-effects, as well as comorbidities and their correlations with metastatic, hormonal and HER2 status.
What do patients know and believe about immunotherapy? CareAcross conducted an extensive study collecting responses from 5,589 cancer patients.
Patient perceptions on Immunotherapy, Support needs, and Medication Adherence presented at the World Conference on Lung Cancer 2021
CareAcross presented real world evidence from cancer patients as reported through the CareAcross platform, in the form of 3 posters, including a featured poster on lung cancer patients’ perceptions on immunotherapy.
The 2021 Annual Congress of the American Society of Clinical Oncology (ASCO) took place in early June. This year, as in 2020, the conference took place virtually and not in Chicago, and therefore the expected crowd of 45,000 attended keynotes and lectures, and viewed abstracts and posters, from across the globe.
The annual congress of American Society of Clinical Oncology is the most important meeting of oncologists worldwide, with about 35,000 delegates. This year, in lung cancer and mesothelioma, several developments were announced with interest to patients.
Melanoma is the most dangerous type of skin cancer. Our Chief Medical Officer reports the latest developments on metastatic melanoma, from the European Oncology conference.
Lung cancer is the most deadly cancer worldwide, claiming the lives of more than 1.5 million people annually. Our Chief Medical Officer attended the 2014 Congress of the European Society for Medical Oncology (ESMO) and summarizes the key findings.
HER2-positive accounts for 1 in 4 breast cancer cases. Metastatic disease is particularly challenging, and researchers have been trying to find a way to support these patients. A new combination of drugs was found very beneficial in a study, and this could help thousands of women worldwide.
A session at the 2014 ASCO meeting focused on targeted adenocarcinoma treatment for specific genetic mutations-a promising option for some lung cancer patients.
The 12th PanCare Meeting for Childhood Cancer survivors was held in Amsterdam, and one session focused on social outcomes. Sabine Karner, PanCare board member, summarizes its main findings.
The 2013 European Cancer Congress included sessions on childhood cancer survivors. Mrs Tsirou, the president of the childhood cancer survivors’ association called “Kyttaro” (based in Greece), summarizes the main findings and observations.